PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 26, 2026Clinical Research in Practice The Journal of Team Hippocrates0 citationsOpen Access

Tadalafil monotherapy is a reasonable alternative for the treatment of lower urinary tract symptoms in patients with comorbid benign prostatic hyperplasia and erectile dysfunction

DIDaniel M. IbrahimAAAnam AhmedSRSwetha Reddy

Key Points

  • To evaluate the effectiveness of tadalafil monotherapy for treating lower urinary tract symptoms in patients with benign prostatic hyperplasia and erectile dysfunction.
  • Conducted an international, randomized, parallel, placebo-controlled clinical trial.
  • Compared the effects of tadalafil and tamsulosin on urinary tract symptoms.
  • Focused on a patient population with comorbid benign prostatic hyperplasia and erectile dysfunction.
  • Both tadalafil and tamsulosin similarly improved lower urinary tract symptoms.
  • Tadalafil was a suitable alternative for patients who discontinued dutasteride due to side effects.

Abstract

A clinical decision report using: Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomized, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61(5):917-925. https://doi.org/10.1016/j.eururo.2012.01.0131 for a vigorous 75-year-old man with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) who discontinued dutasteride due to intolerable sexual side effects.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ibrahim et al. (2026) studied this question.

synapsesocial.com/papers/699fe36b95ddcd3a253e7396https://doi.org/10.22237/crp/1770638400
Ask AI
Helpful
Bookmark
Share
View Full Paper